Science & Enterprise subscription

Follow us on Twitter

  • New post on Science and Enterprise: Shana Tova 5781 #Science #Business
    about 2 days ago
  • When even PhRMA doesn't want to be a Trump campaign prop ... A Deal on Drug Prices Undone by White House Insistence…
    about 3 days ago
  • A company developing a drug for depression based on synthesized compounds in hallucinogenic substances is raising $…
    about 3 days ago
  • New post on Science and Enterprise: Mental Health Drug Company Raises $127.5M in IPO #Science #Business
    about 3 days ago
  • A test for SARS-CoV-2 viruses is shown in field tests to return diagnostic results in 90 minutes with accuracy comp…
    about 3 days ago

Please share Science & Enterprise

Patent Granted for Lung Disorder Treatment

Illustration of lungs (Mikael Häggström/Wikimedia Commons)

(Mikael Häggström/Wikimedia Commons)

Discovery Laboratories Inc., a biotechnology company in Warrington, Pennsylvania, said today the company received a U.S. patent for its treatment of pulmonary inflammation. The patent — number 7,863,241 — expires in 2023.

Discovery Labs says the patent covers its KL4 peptide (also known as sinapultide), an engineered pulmonary surfactant that lowers surface tension and promote oxygen exchange. The patented treatment delivers an array of protease inhibitors, administered as either a liquid or aerosol, for treating pulmonary inflammation.

The company credits Charles Cochrane, co-founder of The Scripps Research Institute, as the original inventor of Discovery Labs’ surfactant technology. The Scripps Research Institute has granted Discovery Labs exclusive licensing rights for this patent.

*     *     *

Comments are closed.